Table 3.

Risk adjusted relative odds of Any Bleeding event, Major Bleeding Event, or Gastrointestinal Bleeding for weeks of dabigatran use relative to weeks of warfarin use

	Odds Ratio (95% CI; p-value)
	Unadjusted	Adjusted for baseline and time-varying patient characteristics
Outpatient or Inpatient Bleeding Episodes
Any Bleeding	1.36 (1.12–1.65; p=.002)	1.27 (1.03–1.56; p=0.02)
Gastrointestinal Hemorrhage	1.71 (1.36–2.16; p<.001)	1.54 (1.20–1.97; p<.001)
Cranial Hemorrhage	0.91 (0.23–3.63; p=0.90)	0.86 (0.21–3.53; p=0.84)
Other site	0.95 (0.68–1.31; p=0.73)	0.97 (0.68–1.39; p=0.88)
Death	0.75 (0.56–0.99; p=0.04)	0.76 (0.49–1.17; p=.20)